Belite linked tinlarebant to a 35.7% reduction in lesion growth rate versus placebo, achieving the study’s primary endpoint.

Protego Biopharma is gearing up to bring its amyloid light-chain (AL) amyloidosis prospect into pivotal testing using its new ...

ARPA-H is seeking proposals from experts in surgery, imaging and AI, including academic and scientific research institutions ...

French vaccine developer Valneva is closing down a site that houses both operational and R&D work, impacting 30 employee roles. | French vaccine maker Valneva is closing down a site that houses both ...

Most AI drug development is fueled by foundation models in biology—models that are trained on vast biological data sets and ...

Hologic has put forward two studies of its artificial intelligence programs for mammography, showing that an AI tool could maintain high breast cancer detection rates while also simplifying radiolo | ...

In what Ceribell is hailing as a first of its kind, the company received a 510 (k) clearance from the FDA for its Clarity ...

The FDA has delayed a decision on Ascendis Pharma’s dwarfism drug candidate TransCon CNP, pushing back the deadline by three ...

Clinical trials succeed or stall based on one factor that’s easy to overlook: how well they fit into patients’ lives. | ...

A federal commission is warning that the U.S. is losing its innovative edge, arguing that the nation needs to “reimagine the ...

The Federal Trade Commission (FTC) has begun outlining its case against Edwards Lifesciences' proposed purchase of heart ...

Single-use technologies (SUT) are well-suited for modular production environments and represent a valuable solution in ...